ArticleScience progress
Predictive value of Lp(a) for MACE in ACS patients with T2DM following PCI, with achieved LDL-C target: A cross-sectional study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveIt is widely accepted that elevated low-density lipoprotein cholesterol (LDL-C) levels are a major risk factor for coronary heart disease (CHD). However, even patients who have achieved LDL-C levels below the currently recommended targets may still have residual risk. Recently, Lipoprotein(a) [Lp(a)] has attracted significant attention as independent causal risk factor for CHD. Nonetheless, the role of Lp(a) in acute coronary syndrome (ACS) patients with type 2 diabetes mellitus (T2DM) who have undergone percutaneous coronary intervention (PCI) and achieved the LDL-C target (≤1.4 mmol/L) remains unclear.MethodsThis retrospective study enrolled 462 ACS patients with comorbid T2DM who underwent PCI, with a median follow-up duration of 27 months post-procedure. The primary endpoint was major adverse cardiovascular events (MACE), defined as all-cause death, recurrent acute myocardial infarction (AMI), ischemic stroke, or hospitalization due to recurrent angina. Based on MACE occurrences, patients were divided into MACE group and non-MACE group. Furthermore, patients were further divided into three groups according to their Lp(a) levels. Kaplan-Meier and Cox regression analyses were performed.ResultsPatients with MACE had more coronary artery lesions, and the plasma Lp(a) concentrations in the MACE group were significantly higher than in the non-MACE group. The incidence of MACE and recurrent AMI was higher in the Lp(a) ≥ 180 mg/dL group compared to the other two groups. Even after multivariate adjustment, Lp(a) ≥ 180 mg/dL remained closely associated with an increased risk of MACE (HR 2.82, 95% CI: 1.47-5.41,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.